One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Shariq Usman, MD,a Tariq Jamal Siddiqi, MD, a Stefan D. Anker, MD,b,c George L. Bakris, MD,d Deepak L. Bhatt, MD, MPH,e Gerasimos Filippatos, MD,f Gregg C. Fonarow, MD,g Stephen J. Greene, MD,h,i James L. Januzzi, J R , MD,j,k Muhammad Shahzeb Khan, MD, MSC ,h Mikhail N. Kosiborod, MD, l Darren K. McGuire, MD, MHS C ,m,n Ileana L. Pi?a, MD, MPH,o Julio Rosenstock, MD,p Muthiah Vaduganathan, MD, MPH,e Subodh Verma, MD,q Shelley Zieroth, MD, r Javed Butler, MD, MPH, MBA
doi : 10.1016/j.jacc.2023.04.034
Volume 81, Issue 25, 27 June 2023, Pages 2377-2387
SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency∗
Stephen D. Wiviott, MD, David D. Berg, MD, MPH
doi : 10.1016/j.jacc.2023.04.035
Volume 81, Issue 25, 27 June 2023, Pages 2388-2390
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
David D. Berg, MD, MPH,a Filipe A. Moura, MD, PHD, a Andrea Bellavia, PHD, a Benjamin M. Scirica, MD, MPH,a Stephen D. Wiviott, MD,a Deepak L. Bhatt, MD, MPH,b Itamar Raz, MD, c Erin A. Bohula, MD, DPHIL ,a Robert P. Giugliano, MD, SM, a Jeong-Gun Park, PH D, a Mark W. Feinberg, MD, d Eugene Braunwald, MD,a David A. Morrow, MD, MPH,a Marc S. Sabatine, MD, MPH
doi : 10.1016/j.jacc.2023.04.031
Volume 81, Issue 25, 27 June 2023, Pages 2391-2402
Risk of atherothrombotic events is not uniform in patients with type 2 diabetes mellitus (T2DM). Tailored risk assessment may help guide selection of pharmacotherapies for cardiovascular primary and secondary prevention.
An Atherothrombotic Risk Score for Patients With Diabetes: Useful Tool or More of the Same?∗
Kent Brummel, MD, Kim Eagle, MD
doi : 10.1016/j.jacc.2023.04.032
Volume 81, Issue 25, 27 June 2023, Pages 2403-2405
Thrombus Burden and Outcomes in Patients With COVID-19 Presenting With STEMI Across the Pandemic
Krishnaraj S. Rathod, MD, P HD, a,b Zhi Teoh, MD, a Angelos Tyrlis, MD,a Fizzah A. Choudry, MD, PH D, a Stephen M. Hamshere, MD, a Katrina Comer, BSC ,a Oliver Guttmann, MD, a Ajay K. Jain, MD, a Muhiddin A. Ozkor, MD, a Andrew Wragg, PHD, a R. Andrew Archbold, MD, a Andreas Baumbach, MD, PH D, a,b Anthony Mathur, MD, P HD, a,b Daniel A. Jones, MD, PH D
doi : 10.1016/j.jacc.2023.04.029
Volume 81, Issue 25, 27 June 2023, Pages 2406-2416
It has been previously reported during the first COVID-19 outbreak that patients presenting with ST-segment elevation myocardial infarction (STEMI) and concurrent COVID-19 infection have increased thrombus burden and poorer outcomes. To date, there have been no reports comparing the outcomes of COVID-19–positive STEMI patients across all waves of the pandemic.
Primary PCI, Thrombus, and COVID-19: Remembrance of Things Past∗
Harold L. Dauerman, MD
doi : 10.1016/j.jacc.2023.04.030
Volume 81, Issue 25, 27 June 2023, Pages 2417-2419
Mortality in Patients With Ebstein Anomaly
Filip Eckerstr?m, MD, PHD, a,b Mikael Dellborg, MD, PHD, c Vibeke Elisabeth Hjortdal, MD, PH D, DMSC ,a,b Peter Eriksson, MD, P HD, c,d Zacharias Mandalenakis, MD, P HD
doi : 10.1016/j.jacc.2023.04.037
Volume 81, Issue 25, 27 June 2023, Pages 2420-2430
Low birth prevalence and referral bias constitute significant obstacles to elucidating the natural history of Ebstein anomaly (EA).
Ebstein Anomaly: We Should Do Better∗
Heidi M. Connolly, MD,a Joseph A. Dearani, MD,b William R. Miranda, MD
doi : 10.1016/j.jacc.2023.05.009
Volume 81, Issue 25, 27 June 2023, Pages 2431-2433
Pulmonary Complications in Patients With Fontan Circulation: JACC Review Topic of the Week
Ali Abdulkarim, MD, a Shawn Shaji, MD, b,c Mahmud Elfituri, MD,a Megan Gunsaulus, MD, b,c Muhammad A. Zafar, MD, MSC ,d Ali N. Zaidi, MD,e Robert H. Pass, MD, f Brian Feingold, MD, MS, b,c Geoffrey Kurland, MD, PH D, g,h Jacqueline Kreutzer, MD,b,c Rod Ghassemzadeh, MD,i Bryan Goldstein, MD, b,c Shawn West, MD, P HD, b,c Tarek Alsaied, MD, MS C
doi : 10.1016/j.jacc.2023.04.036
Volume 81, Issue 25, 27 June 2023, Pages 2434-2444
The Fontan operation has resulted in significant improvement in survival of patients with single ventricle physiology. As a result, there is a growing population of individuals with Fontan physiology reaching adolescence and adulthood. Despite the improved survival, there are long-term morbidities associated with the Fontan operation.
ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease
doi : 10.1016/j.jacc.2023.03.410
Volume 81, Issue 25, 27 June 2023, Pages 2445-2467
Developing Future Clinical Trialists: Increasing Fellow Exposure to Clinical Trials During Training
Jason Feinman, MD, a Jana Lovell, MD, b Christabel Nyange, MD, MPH
doi : 10.1016/j.jacc.2023.04.027
Volume 81, Issue 25, 27 June 2023, Pages 2468-2471
RESPONSE: The CardioNerds Clinical Trial Network: A Model for Inspiring the Next Generation of Trialists
Robert J. Mentz, MD,a Anuradha Lala, MD
doi : 10.1016/j.jacc.2023.04.039
Volume 81, Issue 25, 27 June 2023, Page 2471
Addressing the Global Burden of CVD Through “ACCelerated� Action
. Hadley Wilson, MD, FACC, President, American College of Cardiology, Kian Keong Poh, MBBC H, FACC, Chair, ACC Assembly of International Governors
doi : 10.1016/j.jacc.2023.05.015
Volume 81, Issue 25, 27 June 2023, Pages 2472-2475
Intrahepatic and Periduodenal Embolization for Protein-Losing Enteropathy Patients With Congenital Heart Disease
Ari J. Gartenberg, MD Ganesh Krishnamurthy, MD Abhay Srinivasan, MD Fernando A. Escobar, MD Jefferson N. Brownell, MD Petar Mamula, MD Michael L. O’Byrne, MD, MSCE Yoav Dori, MD, PhD *Christopher L. Smith, MD, PhD
doi : 10.1016/j.jacc.2023.04.033
Volume 81, Issue 25, 27 June 2023, Pages 2476-2478
